Society of Dermatology Physician Assistants (SDPA) Fall, 2023

Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials

Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumor necrosis factor inhibitors: Results from the Phase 3 BE COMPLETE study and its open-label extension up to 1 year